Abstract:Background Glymphatic dysfunction is a crucial pathway for dementia. Alzheimer’s disease (AD) pathologies co-existing with cerebral small vessel disease (CSVD) is the most common pathogenesis for dementia. We hypothesize that AD pathologies and CSVD could be associated with glymphatic dysfunction, contributing to cognitive impairment. Method Participants completed with amyloid PET, diffusion tensor imaging (DTI), and T2 fluid-attenuated inversion-recovery (FLAIR) sequences were included from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). White matter hyperintensities (WMH), the most common CSVD marker, was evaluated from T2FLAIR images and represented the burden of CSVD. Amyloid PET was used to assess Aβ aggregation in the brain. We used diffusion tensor image analysis along the perivascular space (DTI-ALPS) index, the burden of enlarged perivascular spaces (PVS), and choroid plexus volume to reflect glymphatic function. The relationships between WMH burden/Aβ aggregation and these glymphatic markers as well as the correlations between glymphatic markers and cognitive function were investigated. Furthermore, we conducted mediation analyses to explore the potential mediating effects of glymphatic markers in the relationship between WMH burden/Aβ aggregation and cognition. Results One hundred and thirty-three participants along the AD continuum were included, consisting of 40 CN − , 48 CN + , 26 MCI + , and 19 AD + participants. Our findings revealed that there were negative associations between whole-brain Aβ aggregation ( r = − 0.249, p = 0.022) and WMH burden ( r = − 0.458, p < 0.001) with DTI-ALPS. Additionally, Aβ aggregation ( r = 0.223, p = 0.041) and WMH burden ( r = 0.294, p = 0.006) were both positively associated with choroid plexus volume. However, we did not observe significant correlations with PVS enlargement severity. DTI-ALPS was positively associated with memory ( r = 0.470, FDR- p < 0.001), executive function ( r = 0.358, FDR- p = 0.001), visual-spatial ( r = 0.223, FDR- p < 0.040), and language ( r = 0.419, FDR- p < 0.001). Conversely, choroid plexus volume showed negative correlations with memory ( r = − 0.315, FDR- p = 0.007), executive function ( r = − 0.321, FDR- p = 0.007), visual-spatial ( r = − 0.233, FDR- p = 0.031), and language ( r = − 0.261, FDR- p = 0.021). There were no significant correlations between PVS enlargement severity and cognitive performance. In the mediation analysis, we found that DTI-ALPS acted as a mediator in the relationship between WMH burden/Aβ accumulation and memory and language performances. Conclusion Our study provided evidence that both AD pathology (Aβ) and CSVD were associated with glymphatic dysfunction, which is further related to cognitive impairment. These results may provide a theoretical basis for new targets for treating AD.

Association of Vascular Risk Factors and Cerebrovascular Pathology With Alzheimer Disease Pathologic Changes in Individuals Without Dementia

Vascular risk burden is a key player in the early progression of Alzheimer’s disease

The Relationship Between Amyloid Pathology, Cerebral Small Vessel Disease, Glymphatic Dysfunction, and Cognition: a Study Based on Alzheimer’s Disease Continuum Participants

Effect of Vascular Risk Factors on Blood-Brain Barrier and Cerebrospinal Fluid Biomarkers Along the Alzheimer's Disease Continuum: A Retrospective Observational Study

Distinct Cerebral Small Vessel Disease Impairment in Early- and Late-Onset Alzheimer's Disease.

Associations of cerebrovascular disease and Alzheimer's disease pathology with cognitive decline: Analysis of the National Alzheimer's Coordinating Center Uniform Data Set

Alzheimer's disease and neurodegeneration in symptomatic cerebral small vessel disease

The Association of Enlarged Perivascular Space with Microglia-Related Inflammation and Alzheimer's Pathology in Cognitively Normal Elderly

Associations Between APOE Genotype and Cerebral Small-Vessel Disease: a Longitudinal Study

The Interaction Between Vascular Risk Factors, Cerebral Small Vessel Disease, and Amyloid Burden in Older Adults

Cerebral Small Vessel Disease Burden Predicts Neurodegeneration and Clinical Progression in Prodromal Alzheimer's Disease

P2-600: CORTICAL ATROPHY MEDIATING THE ACCUMULATING EFFECTS OF VASCULAR RISK FACTORS ON COGNITION IN ALZHEIMER'S DISEASE SPECTRUM

Cerebral Small Vessel Disease in Sporadic and Familial Alzheimer Disease

IC-P-101: CORTICAL ATROPHY MEDIATING THE ACCUMULATING EFFECTS OF VASCULAR RISK FACTORS ON COGNITION IN ALZHEIMER'S DISEASE SPECTRUM

Alzheimer's Disease and Small Vessel Disease Differentially Affect White Matter Microstructure

Vascular contributions to Alzheimer's disease

Neuroinflammation and amyloid deposition in the progression of mixed Alzheimer and vascular dementia

Contributions of amyloid beta and cerebral small vessel disease in clinical decline

Cerebral Microbleeds, Cerebral Amyloid Angiopathy, and Their Relationships to Quantitative Markers of Neurodegeneration

Vascular disease and risk factors are associated with cognitive decline in the alzheimer disease spectrum

Cerebrovascular disease drives Alzheimer plasma biomarker concentrations in adults with Down syndrome